The genus Aeromonas has been recognised as an important pathogenic species in aquaculture that causes motile Aeromonas septicaemia (MAS) or less severe, chronic infections. This study compares the pathogenicity of the different Aeromonas spp. that were previously isolated from freshwater fish with signs of MAS. A total of 124 isolates of Aeromonas spp. were initially screened for the ability to grow on M9 agar with myo-inositol as a sole carbon source, which is a discriminatory phenotype for the hypervirulent A. hydrophila (vAh) pathotype. Subsequently, LD50 of six selected Aeromonas spp. were determined by intraperitoneal injection of bacterial suspension containing 103, 105, and 107 CFU/mL of the respective Aeromonas sp. to red hybrid tilapias. The kidneys, livers and spleens of infected moribund fish were examined for histopathological changes. The screening revealed that only A. dhakensis 1P11S3 was able to grow using myo-inositol as a sole carbon source, and no vAh strains were identified. The LD50–240h of A. dhakensis 1P11S3 was 107 CFU/mL, while the non-myo-inositol utilizing A. dhakensis 4PS2 and A. hydrophila 8TK3 was lower at 105 CFU/mL. Similarly, tilapia challenged with the myo-inositol A. dhakensis 1P11S3 showed significantly (p < 0.05) less severe signs, gross and histopathological lesions, and a lower mortality rate than the non-myo-inositol A. dhakensis 4PS2 and A. hydrophila 8TK3. These findings suggested that myo-inositol utilizing A. dhakensis 1P11S3 was not a hypervirulent Aeromonas sp. under current experimental disease challenge conditions, and that diverse Aeromonas spp. are of concern in aquaculture farmed freshwater fish. Therefore, future study is warranted on genomic level to further elucidate the influence of myo-inositol utilizing ability on the pathogenesis of Aeromonas spp., since this ability correlates with hypervirulence in A. hydrophila strains.
Vibrio spp. are important aquaculture pathogens that cause vibriosis, affecting large numbers of marine fish species. This study determines the field efficacy of a feed-based inactivated vaccine against vibriosis in cage-cultured Asian seabass. A total of 4800 Asian seabass, kept in a field environment, were separated equally into two groups (vaccinated and non-vaccinated) in duplicate. Fish of Group 1 were orally administered the feed-based vaccine on weeks 0 (prime vaccination), 2 (booster), and 6 (second booster) at 4% body weight, while the non-vaccinated fish of Group 2 were fed with a commercial formulated pellet without the vaccine. Fish gut, mucus, and serum were collected, the length and weight of the fish were noted, while the mortality was recorded at 2-week intervals for a period of 16 weeks. The non-specific lysozyme activities were significantly (p < 0.05) higher in the fish of Group 1 than the non-vaccinated fish of Group 2. Similarly, the specific IgM antibody levels in serum and mucus were significantly (p < 0.05) higher in Group 1 than in Group 2, as seen in the second week, with the highest level 8 weeks after primary immunization. At week 16, the growth performance was significantly (p < 0.05) better in Group 1 and showed lower bacterial isolation in the gut than Group 2. Despite the statistical insignificance (p > 0.05), the survival rate was slightly higher in Group 1 (71.3%) than Group 2 (67.7%). This study revealed that feed-based vaccination improves growth performance, stimulates innate and adaptive immune responses, and increases protection of cultured Asian seabass, L. calcarifer, against vibriosis.
29 March 2023 in Pertanika Journal of Tropical Agricultural Science
This study evaluates the potential of microalgae, Chlorella vulgaris , and black soldier fly larvae (BSFL), Hermetia illucens , as an alternative complete diet for red hybrid tilapia, addressing challenges arising from declining fish stocks and unsustainable aquaculture practices reliant on fish meal in commercial pellets. The study involved 270 tilapia separated into three groups: Group 1 received C. vulgaris alone, Group 2 was fed with a combination of BSFL and C. vulgaris , and Group 3 with commercial pellets (control) for 70 days. The results demonstrated that the combination of BSFL and C. vulgaris had a high potential to be an alternative to commercial pellets, with comparable growth performance with the control group. In contrast, fish‐fed with C. vulgaris alone exhibited significantly slower growth rates and higher mortality. Economic analysis showed that the BSFL and C. vulgaris combination reduced feed costs by 59.40% and increased the profit index by 144.79% compared to the control group. However, the combination diet did not provide significant protection against streptococcosis compared to commercial pellets. This study highlights the potential of incorporating BSFL and C. vulgaris into tilapia diets to enhance sustainability and economic outcomes for farmers. It also emphasizes the role of alternative feeds in promoting environmentally sustainable aquaculture practices, with the goal of achieving zero‐carbon emissions. This study is the earliest report on the direct combination of BSFL and C. vulgaris diet in tilapia, a globally cultivated aquaculture fish species.
Vibriosis, caused by Vibrio spp ., poses a significant challenge in marine aquaculture, leading to severe economic losses. Vaccination has emerged as a safer and more effective alternative to antibiotics for disease control, with oral vaccination offering advantages such as ease of administration and scalability for large‐scale aquaculture operations. This study evaluated the efficacy of an oral inactivated Vibrio harveyi vaccine in a field environment with cage‐cultured Asian seabass ( Lates calcarifer ) at Pulau Ketam, Klang, Selangor, Malaysia. Fish were divided into two groups: (1) a vaccinated group fed a commercial diet supplemented with formalin‐killed V. harveyi (10 8 CFU/mL) and palm oil as an adjuvant and (2) a placebo control group fed a commercial diet supplemented with phosphate‐buffered saline (PBS) and palm oil adjuvant. The vaccine was administered orally at weeks 0, 2, and 6 for three consecutive days at a dosage of 4% of the fish’s body weight. Immune‐related gene expression, including dendritic cells (DCs), complement factor 3 (C3), chemokine ligand 4 (CCL4), tumor necrosis factor‐α (TNF‐α), and immunoglobulin‐T (IgT), was significantly upregulated ( p < 0.05) in vaccinated fish compared to controls, with peak expression observed following booster doses. At week 10, a laboratory challenge trial with V. harveyi (1 × 10 8 CFU/mL) demonstrated an 80% relative percentage survival (RPS) in the vaccinated group, whereas the unvaccinated group exhibited 100% mortality. In addition, vaccinated fish displayed reduced clinical signs following infection. These findings highlight the potential of oral inactivated V. harveyi vaccines to induce robust immune responses and confer effective protection against vibriosis in Asian seabass. This approach provides a practical and scalable solution for disease management in marine aquaculture, improving health outcomes and productivity for fish farmers.